Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fespixon
- Development stage
- Phase 4
- Lead developer
- Oneness Biotech
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
**Fespixon** is a prescription topical natural-product cream developed by Oneness Biotech for diabetic foot ulcers. Also known as **ON101**, it is a standardized botanical formulation containing *Centella asiatica* extract S1 and *Plectranthus amboinicus* extract PA-F4. It is intended to rebalance the chronic wound microenvironment by reducing pro-inflammatory M1 macrophage activity, promoting pro-healing M2a and M2c macrophage phenotypes, and inducing adipose precursor cell secretion of G-CSF and CXCL3. This macrophage-regulating activity is associated with enhanced keratinocyte proliferation, angiogenesis, collagen formation, tissue repair, and wound closure. Fespixon has marketing approvals for diabetic foot ulcer treatment in several Asian markets, including Taiwan, Singapore, Malaysia, China, and Indonesia. ([onenessbio.com](https://onenessbio.com/en/pipeline-en/fespixon-zone-en/fespixon-cream-en/))
- Brand names
- Fespixon速必一
- Other names
- ON101 CreamON-101 CreamON 101 CreamXianglei Tangzu CreamXianglei Tangzu Gao香雷糖足膏
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)CXCL3
Beyond the preview
Go deeper on Fespixon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fespixon.